Efficacy and safety of Mirabegron for treatment OAB in the postmenopausal female patients -Evaluation using Pressure Flow Study

Efficacy and safety of Mirabegron for treatment OAB in the postmenopausal female patients -Evaluation using Pressure Flow Study - Efficacy of Mirabegron using Pressure Flow Study

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000019272

Enrollment

Registered

2015-10-08

Start date

2012-07-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

overactive bladder

Interventions

Mirabegron 50mg/day for 12 weeks

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Inclusion criteria were as follows: total OAB symptom scores (OABSS) of 3; urgency episodes 1 per week; post-menopausal women; and age 50 years.

Exclusion criteria

Exclusion criteria: Patients were excluded if they received oral anticholinergic agents, alpha1-blockers, antidepressants, or anti-anxiety agents; had obvious neurogenic bladder dysfunction, bladder calculi, or active urinary tract infection; or had severe cardiac disease, renal dysfunction (serum-creatinine;2 mg/dL), and/or hepatic dysfunction (i.e., aspartate aminotransferase and alanine aminotransferase levels of more than twice the normal value).

Design outcomes

Primary

Measure	Time frame
the change of storage and voiding function before and after administration	—

Secondary

Measure	Time frame
the change of subjective symptom (IPSS, OABSS) before and after administration	—

Countries

Japan

Contacts

Public ContactYoshihisa Matsukawa

Nagoya University Graduate School of Medicine Urology

yoshi44@med.nagoya-u.ac.jp+81-52-744-2985

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026